Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEB4 days ago · Sarclisa-VRd also met several secondary endpoints which demonstrated deep responses in this patient population: Approximately three-quarters (74.7%) of patients treated with Sarclisa-VRd achieved a complete response (CR) or better compared to 64.1% of patients taking VRd (OR 1.7; 95% CI: 1.097-2.5; p=0.0160).
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple …
WEB1 day ago · REGN. Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in ...
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
WEB2 days ago · Sarclisa made around $413 million in sales for Sanofi last year, a fraction of the $9.7 billion booked by J&J for Darzalex, so having a niche free of competition from its rival could translate to ...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
WEB2 days ago · On Saturday, the FDA approved Sanofi’s SA (NASDAQ:SNY) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult ...
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible …
WEB4 days ago · Sarclisa was approved by the FDA in 2020 in combination with pomalidomide and dexamethasone for adults with multiple myeloma who received at least two prior therapies including lenalidomide and a proteasome inhibitor. In 2021, it was approved by the agency in combination with Kyprolis (carfilzomib) and dexamethasone to …
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Room - Sanofi US News
WEBMay 27, 2024 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activities.
Sarclisa Approved for Transplant-Ineligible Newly Diagnosed …
WEB21 hours ago · Sarclisa is supplied as a 100 mg/5 mL and 500 mg/25 mL solution in single-dose vials. This article originally appeared on MPR. ... News release. Sanofi. September 20, 2024.
Press Release: Sarclisa approved in the US as the first anti
WEB4 days ago · In the IMROZ study, Sarclisa-VRd followed by Sarclisa-Rd met the primary endpoint of PFS, significantly reducing the risk of recurrence or death by 40%, compared to VRd followed by Rd, in patients ...
- Some results have been removed